YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK)
HKD 12.66
(2.76%)
HKD 12.66
(2.76%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 2.35 Billion CNY | 629.48% |
| 2022 | 322.72 Million CNY | 170.45% |
| 2021 | -458.1 Million CNY | -154.95% |
| 2020 | 833.69 Million CNY | -67.04% |
| 2019 | 2.52 Billion CNY | 133.47% |
| 2018 | 1.08 Billion CNY | 42.09% |
| 2017 | 762.48 Million CNY | 81.73% |
| 2016 | 419.56 Million CNY | 27.37% |
| 2015 | 329.41 Million CNY | 78.89% |
| 2014 | 184.14 Million CNY | 90.33% |
| 2013 | 96.75 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 867.38 Million CNY | -9.28% |
| 2023 Q2 | 1.48 Billion CNY | 1764.77% |
| 2023 FY | 2.35 Billion CNY | 629.48% |
| 2023 Q4 | 956.07 Million CNY | -35.59% |
| 2022 Q4 | 79.6 Million CNY | -67.26% |
| 2022 FY | 322.72 Million CNY | 170.45% |
| 2022 Q2 | 243.11 Million CNY | 556.93% |
| 2021 FY | -458.1 Million CNY | -154.95% |
| 2021 Q2 | -495.11 Million CNY | -553.46% |
| 2021 Q4 | 37 Million CNY | 107.47% |
| 2020 Q2 | 909.46 Million CNY | -26.04% |
| 2020 FY | 833.69 Million CNY | -67.04% |
| 2020 Q4 | -75.76 Million CNY | -108.33% |
| 2019 FY | 2.52 Billion CNY | 133.47% |
| 2019 Q4 | 1.22 Billion CNY | -5.41% |
| 2019 Q2 | 1.29 Billion CNY | 281.44% |
| 2018 FY | 1.08 Billion CNY | 42.09% |
| 2018 Q4 | 340.79 Million CNY | -54.11% |
| 2018 Q2 | 742.64 Million CNY | 84.74% |
| 2017 Q2 | 360.49 Million CNY | 138.72% |
| 2017 FY | 762.48 Million CNY | 81.73% |
| 2017 Q4 | 401.98 Million CNY | 11.51% |
| 2016 Q2 | 268.55 Million CNY | 103.83% |
| 2016 FY | 419.56 Million CNY | 27.37% |
| 2016 Q4 | 151.01 Million CNY | -43.77% |
| 2015 Q2 | 197.66 Million CNY | 173.81% |
| 2015 Q4 | 131.75 Million CNY | -33.34% |
| 2015 FY | 329.41 Million CNY | 78.89% |
| 2014 Q2 | 111.95 Million CNY | 117.98% |
| 2014 Q4 | 72.19 Million CNY | -35.52% |
| 2014 FY | 184.14 Million CNY | 90.33% |
| 2013 FY | 96.75 Million CNY | 0.0% |
| 2013 Q4 | 51.36 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 143.01 Million HKD | -1546.154% |
| Grand Pharmaceutical Group Limited | 2.66 Billion HKD | 11.609% |
| Extrawell Pharmaceutical Holdings Limited | -8.16 Million HKD | 28943.396% |
| Wai Yuen Tong Medicine Holdings Limited | 40.88 Million HKD | -5658.801% |
| Qianhai Health Holdings Limited | -52.18 Million HKD | 4611.427% |
| Lee's Pharmaceutical Holdings Limited | 36.04 Million HKD | -6431.818% |
| Essex Bio-Technology Limited | 310.32 Million HKD | -658.612% |
| Tongfang Kontafarma Holdings Limited | - HKD | -Infinity% |
| PuraPharm Corporation Limited | -66.04 Million HKD | 3664.482% |
| SSY Group Limited | 1.63 Billion HKD | -43.645% |
| JBM (Healthcare) Limited | 174.2 Million HKD | -1251.395% |
| Jacobson Pharma Corporation Limited | 333.12 Million HKD | -606.699% |
| China Resources Pharmaceutical Group Limited | 12.14 Billion HKD | 80.619% |